Rapid Itch Relief Seen with Nemolizumab
January 8, 2026
-
3 min
7 Key Takeaways
-
1
Nemolizumab-ilto targets interleukin-3
-
2
Significant improvements in itch were noted by day
-
3
Patients showed increased response at day 1
-
4
Analyses involved 1,728 patients with AD and 560 with PN.
-
5
Itch measured using PP-NRS, sleep disturbance with SD-NRS.
-
6
Early response linked to sustained benefits at week 1
-
7
Study results emphasize the importance of IL-31 pathway in itch relief.
Nemolizumab-ilto, a humanized monoclonal antibody targeting interleukin-31, demonstrated significant reductions in itch and sleep disturbances within just two days for patients suffering from moderate-to-severe atopic dermatitis and prurigo nodularis. A post hoc analysis of four phase 3 randomized clinical trials revealed that more patients on nemolizumab reported substantial improvements in itch intensity compared to placebo, with these effects growing over the first two weeks. This could lead to improved patient quality of life.
Listen Tab content
